Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals

Set Alert for Deals

Lupin Launches First Cetuximab Biosimilar In India Through Enzene Partnership

Lupin has collaborated with Alkem subsidiary Enzene Biosciences to launch the first ever cetuximab biosimilar in India. 

Biosimilars Launches

UAE’s Bioventure Is Looking For Partners To Expand

Having recently added to its biosimilars alliance with Alvotech, Dubai-based Bioventure says it is looking to expand its international reach through further partnerships.

Strategy Deals

Alvotech Makes Multiple Moves As It Allies With Advanz For Five European Biosimilars

In a busy week for Alvotech, the firm has announced an expansion of its partnership with Advanz to cover five further European biosimilars, at the same time as revealing two new pipeline assets. Meanwhile, the company has also dropped three products from an existing European partnership with Stada and has also terminated a development deal with BiosanaPharma.

Deals Biosimilars

Stelara Settlement Gives Amgen US Ustekinumab Entry Date

A settlement reached in US patent litigation over Janssen’s Stelara will allow Amgen to launch its ABP 654 ustekinumab biosimilar no later than 1 January 2025. It remains to be seen whether other ustekinumab developers will follow suit.

Biosimilars Deals

Is The Bloom Off The Rose For Big Pharma And Biosimilars?

After a wave of big pharma interest in the biosimilars arena, originator enthusiasm for the sector appears to be waning – potentially opening up an opportunity for newcomers to compete on off-patent biologics.

Biosimilars Strategy

Neuraxpharm Rebrands Spanish Subsidiary As It Focuses On European Profile

Neuraxpharm has rebranded a Spanish finished dosage form facility to mark its “full integration” within the group, as it focuses on building its profile in Europe.

Strategy Advertising, Marketing & Sales

Alvotech Links Up With Polifarma On Proposed Eylea Biosimilar

Alvotech has signed an agreement with Polifarma to distribute its proposed aflibercept biosimilar in Turkey. The compound, AVT06, is currently in the development stage.

Biosimilars Turkey

Sandoz Makes Major Moves To Bolster Biosimilars Ahead Of Spinoff

Sandoz has made further preparations to bolster its biosimilars business ahead of its spinoff from parent company Novartis, announcing a development and manufacturing deal with Evotec at the same time as unveiling a further investment in its Holzkirchen site to transform it into a biotech development hub.

Biosimilars Deals

EirGenix Looks For Partner As Pertuzumab Passes Phase I

With EirGenix about to start Phase III trials for its proposed biosimilar version of Perjeta, the Taiwanese developer says it is negotiating with global firms for rights to the pertuzumab candidate.

Biosimilars Clinical Trials
See All
UsernamePublicRestriction

Register